Compare VCIG & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VCIG | JAGX |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 4.4M |
| IPO Year | 2023 | N/A |
| Metric | VCIG | JAGX |
|---|---|---|
| Price | $0.84 | $1.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 1.8M | ★ 9.6M |
| Earning Date | 05-08-2026 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $32,903,041.00 | $11,785,000.00 |
| Revenue This Year | N/A | $22.41 |
| Revenue Next Year | N/A | $30.00 |
| P/E Ratio | $0.87 | ★ N/A |
| Revenue Growth | ★ 24.77 | 12.45 |
| 52 Week Low | $0.51 | $0.64 |
| 52 Week High | $978.00 | $25.75 |
| Indicator | VCIG | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 49.53 | 62.17 |
| Support Level | $0.73 | $0.64 |
| Resistance Level | $1.14 | $1.14 |
| Average True Range (ATR) | 0.13 | 0.18 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 53.04 | 67.88 |
VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.